{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:49:30Z","timestamp":1782341370476,"version":"3.54.5"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s12325-023-02766-w","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T08:01:45Z","timestamp":1711785705000},"page":"2010-2027","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-2559","authenticated-orcid":false,"given":"Rose J.","family":"Hart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareen","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4204-6272","authenticated-orcid":false,"given":"Sarah","family":"Alulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4423-0098","authenticated-orcid":false,"given":"Karl W.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Norma","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-8456","authenticated-orcid":false,"given":"Dawn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"key":"2766_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100070","volume":"2","author":"J Reves","year":"2021","unstructured":"Reves J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov. 2021;2:100070.","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"1","key":"2766_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2019-216151","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Weinblatt ME, Bathon J, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Ann Rheum Dis. 2020;79(1):88\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2766_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496\u2013509.","journal-title":"N Engl J Med"},{"issue":"9","key":"2766_CR4","first-page":"626","volume":"87","author":"N Weigle","year":"2013","unstructured":"Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013;87(9):626\u201333.","journal-title":"Am Fam Physician"},{"key":"2766_CR5","unstructured":"World Health Organization. Global report on psoriasis. 2016. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/204417\/9789241565189_eng.pdf. Accessed 13 Dec 2022."},{"key":"2766_CR6","doi-asserted-by":"crossref","unstructured":"Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9\u201320.","DOI":"10.1590\/abd1806-4841.20153038"},{"issue":"1","key":"2766_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46\u201354 (e42; quiz e30).","journal-title":"Gastroenterology"},{"issue":"6","key":"2766_CR8","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/ibd.21506","volume":"17","author":"B Pariente","year":"2011","unstructured":"Pariente B, Cosnes J, Danese S, et al. Development of the Crohn\u2019s disease digestive damage score, the Lemann score. Inflamm Bowel Dis. 2011;17(6):1415\u201322.","journal-title":"Inflamm Bowel Dis"},{"issue":"10080","key":"2766_CR9","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756\u201370.","journal-title":"Lancet"},{"issue":"8","key":"2766_CR10","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1111\/j.1572-0241.2002.05842.x","volume":"97","author":"E Guthrie","year":"2002","unstructured":"Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn\u2019s disease. Am J Gastroenterol. 2002;97(8):1994\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"2766_CR11","first-page":"643","volume":"75","author":"MI Zlatkovic-Svenda","year":"2016","unstructured":"Zlatkovic-Svenda MI, Saraux A, Tuncer T, et al. FRI0558 rheumatoid arthritis prevalence in Europe, a Eular-endorsed survey. Ann Rheum Dis. 2016;75(Suppl 2):643.","journal-title":"Ann Rheum Dis"},{"issue":"10055","key":"2766_CR12","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"4","key":"2766_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41(4):545\u201368.","journal-title":"Rheum Dis Clin N Am"},{"issue":"5","key":"2766_CR14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/rheumatology\/keu398","volume":"54","author":"R Giacomelli","year":"2015","unstructured":"Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology (Oxford). 2015;54(5):792\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2766_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"3","key":"2766_CR16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.semarthrit.2018.05.010","volume":"48","author":"P Mease","year":"2018","unstructured":"Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018;48(3):436\u201348.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2766_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.rdc.2012.09.003","volume":"38","author":"C Stolwijk","year":"2012","unstructured":"Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiology of spondyloarthritis. Rheum Dis Clin North Am. 2012;38(3):441\u201376.","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"2766_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","volume":"53","author":"LE Dean","year":"2014","unstructured":"Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2766_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/imm.13242","volume":"161","author":"A Voruganti","year":"2020","unstructured":"Voruganti A, Bowness P. New developments in our understanding of ankylosing spondylitis pathogenesis. Immunology. 2020;161(2):94\u2013102.","journal-title":"Immunology"},{"issue":"5","key":"2766_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.semarthrit.2014.10.009","volume":"44","author":"A Boonen","year":"2015","unstructured":"Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556\u201362.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2766_CR21","doi-asserted-by":"publisher","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","volume":"5","author":"C Lopez-Medina","year":"2019","unstructured":"Lopez-Medina C, Ramiro S, van der Heijde D, Sieper J, Dougados M, Molto A. Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5(2):e001108.","journal-title":"RMD Open"},{"issue":"5","key":"2766_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","volume":"53","author":"B Verstockt","year":"2018","unstructured":"Verstockt B, Ferrante M, Vermeire S, Van Assche G. New treatment options for inflammatory bowel diseases. J Gastroenterol. 2018;53(5):585\u201390.","journal-title":"J Gastroenterol"},{"issue":"Suppl 1","key":"2766_CR23","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","volume":"59","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(Suppl 1):i37\u201346.","journal-title":"Rheumatology (Oxford)"},{"key":"2766_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4447","volume":"372","author":"C Ritchlin","year":"2021","unstructured":"Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: new advances in diagnosis and management. BMJ. 2021;372:m4447.","journal-title":"BMJ"},{"issue":"1","key":"2766_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2766_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/ard-2022-223335","volume":"82","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis GE, Nikiphorou E, Dey M, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742\u201353.","journal-title":"Ann Rheum Dis"},{"key":"2766_CR27","unstructured":"Dignass A, Dotan I, Lindsay J. Evolving treatment options for patients with ulcerative colitis (UC). 2022. https:\/\/www.ecco-ibd.eu\/publications\/ecco-news\/item\/2022-1-evolving-treatment-options-for-patients-with-ulcerative-colitis-uc.html. Accessed  30 May\u00a02023."},{"key":"2766_CR28","unstructured":"National Health Service England. Commissioning framework for biological medicines (including biosimilar medicines). 2017. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2017\/09\/biosimilar-medicines-commissioning-framework.pdf. Accessed  13 Dec 2022."},{"key":"2766_CR29","unstructured":"National Institute for Health and Care Excellence. Systemic biological therapy for psoriasis. 2021. https:\/\/pathways.nice.org.uk\/pathways\/psoriasis\/systemic-biological-therapy-for-psoriasis.pdf.  Accessed 10 Feb 2022."},{"key":"2766_CR30","doi-asserted-by":"crossref","unstructured":"Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12:625296.","DOI":"10.3389\/fphar.2021.625296"},{"issue":"Suppl_1","key":"2766_CR31","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1093\/ecco-jcc\/jjab076.220","volume":"15","author":"B Antolin-Fontes","year":"2021","unstructured":"Antolin-Fontes B, Borsi A, Nissinen R, et al. P091 Switching to TNFi versus non-TNFi biologics in Crohn\u2019s disease patients: real-world outcomes from a German claims data analysis. J Crohns Colitis. 2021;15(Suppl_1):S189\u201391.","journal-title":"J Crohns Colitis"},{"issue":"Suppl 2","key":"2766_CR32","first-page":"701","volume":"78","author":"P Bogas","year":"2019","unstructured":"Bogas P, Plasencia C, Navarro-Compan V, et al. FRI0079 Long-term clinical efficacy of cycling vs switching to a non-TNF inhibitor in RA patients who failed to a first TNF inhibitor. Ann Rheum Dis. 2019;78(Suppl 2):701.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2766_CR33","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1080\/13696998.2021.1970953","volume":"24","author":"A Egeberg","year":"2021","unstructured":"Egeberg A, Dan\u00f8 A, Pedersen M, Sohrt A, Borg E, Notario J. Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain. J Med Econ. 2021;24(1):1134\u201342.","journal-title":"J Med Econ"},{"issue":"5","key":"2766_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/bjd.16247","volume":"178","author":"SL Klijn","year":"2018","unstructured":"Klijn SL, van den Reek JMPA, van de Wetering G, van der Kolk A, de Jong EMGJ, Kievit W. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10\u00a0years of Dutch real-world evidence from BioCAPTURE. Br J Dermatol. 2018;178(5):1181\u20139.","journal-title":"Br J Dermatol"},{"key":"2766_CR35","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1177\/1759720X211002682","volume":"13","author":"A Migliore","year":"2021","unstructured":"Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E. Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:2682.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2766_CR36","unstructured":"Chang W, Cheng J, Allaire JJ, et al. Shiny. Web Application Framework for R. 2021. https:\/\/CRAN.R-project.org\/package=shiny. Accessed 23 Oct 2022."},{"issue":"11","key":"2766_CR37","doi-asserted-by":"publisher","first-page":"e3060","DOI":"10.1097\/MD.0000000000003060","volume":"95","author":"C Chen","year":"2016","unstructured":"Chen C, Zhang X, Xiao L, Zhang X, Ma X. Comparative effectiveness of biologic therapy regimens for ankylosing spondylitis: a systematic review and a network meta-analysis. Medicine (Baltimore). 2016;95(11):e3060.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2766_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE\u00a02 study. Ann Rheum Dis. 2017;76(3):571\u201392.","journal-title":"Ann Rheum Dis"},{"key":"2766_CR39","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment report - Cimzia. Procedure No. EMEA\/H\/C\/001037\/II\/0065. 26 April 2018. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/cimzia-h-c-1037-ii-0065-epar-assessment-report-variation_en.pdf.  Accessed 26 Nov 2019."},{"issue":"20","key":"2766_CR40","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"2766_CR41","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/03007995.2019.1580094","volume":"35","author":"A Varu","year":"2019","unstructured":"Varu A, Wilson FR, Dyrda P, Hazel M, Hutton B, Cameron C. Treatment sequence network meta-analysis in Crohn\u2019s disease: a methodological case study. Curr Med Res Opin. 2019;35(5):733\u201356.","journal-title":"Curr Med Res Opin"},{"key":"2766_CR42","unstructured":"National Institute for Health and Care Excellence. Golimumab for treating non-radiographic axial spondyloarthritis. 2018. https:\/\/www.nice.org.uk\/guidance\/ta497.  Accessed 26 Nov 2019."},{"issue":"3","key":"2766_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE\u00a01 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2766_CR44","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE\u00a02 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2766_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/2475530318818816","volume":"4","author":"C Cameron","year":"2019","unstructured":"Cameron C, Druchok C, Hutton B, et al. Guselkumab for the treatment of moderate-to-severe plaque psoriasis during induction phase: a systematic review and network meta-analysis. J Psoriasis Psoriatic Arthritis. 2019;4(2):81\u201392.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"3","key":"2766_CR46","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"10230","key":"2766_CR47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"issue":"10230","key":"2766_CR48","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase\u00a03 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"4","key":"2766_CR49","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/rheumatology\/keac500","volume":"62","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2023;62(4):1417\u201325.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2766_CR50","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424\u201337.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"2766_CR51","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s12325-019-00912-x","volume":"36","author":"E Choy","year":"2019","unstructured":"Choy E, Freemantle N, Proudfoot CI, et al. Indirect treatment comparison of the efficacy and safety of sarilumab monotherapy in rheumatoid arthritis patients with inadequate response to conventional disease-modifying antirheumatic drugs. Adv Ther. 2019;36(4):817\u201327.","journal-title":"Adv Ther"},{"issue":"4","key":"2766_CR52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/03007995.2020.1716701","volume":"36","author":"M Welty","year":"2020","unstructured":"Welty M, Mesana L, Padhiar A, et al. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Curr Med Res Opin. 2020;36(4):595\u2013606.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2766_CR53","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","volume":"71","author":"JD Greenberg","year":"2012","unstructured":"Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012;71(7):1134\u201342.","journal-title":"Ann Rheum Dis"},{"key":"2766_CR54","unstructured":"National Institute for Health and Care Excellence. Secukinumab for treating non-radiographic axial spondyloarthritis (TA719). 2021. https:\/\/www.nice.org.uk\/guidance\/ta719. Accessed 8 Sept 2022."},{"key":"2766_CR55","unstructured":"National institute for Health and Care Excellence. Risankizumab for treating moderate to severe plaque psoriasis (TA596). 2019. https:\/\/www.nice.org.uk\/guidance\/ta596. Accessed 8 Oct 2022."},{"key":"2766_CR56","unstructured":"National Institute for Health and Care Excellence. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711). 2021. https:\/\/www.nice.org.uk\/guidance\/ta711. Accessed 8 Oct 2022."},{"issue":"3","key":"2766_CR57","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00296-018-4194-y","volume":"39","author":"L Jacob","year":"2019","unstructured":"Jacob L, Chevalier T, Kostev K. Persistence with biological drugs in patients treated in rheumatology practices in Germany. Rheumatol Int. 2019;39(3):525\u201331.","journal-title":"Rheumatol Int"},{"issue":"7","key":"2766_CR58","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/apt.13754","volume":"44","author":"T Billiet","year":"2016","unstructured":"Billiet T, Cleynen I, Ballet V, et al. Prognostic factors for long-term infliximab treatment in Crohn\u2019s disease patients: a 20-year single centre experience. Aliment Pharmacol Ther. 2016;44(7):673\u201383.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2766_CR59","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/ijd.14429","volume":"58","author":"T Lunder","year":"2019","unstructured":"Lunder T, Zorko MS, Kolar NK, et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019;58(6):631\u201341.","journal-title":"Int J Dermatol"},{"issue":"2","key":"2766_CR60","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10620-016-4398-5","volume":"62","author":"C Taxonera","year":"2017","unstructured":"Taxonera C, Iglesias E, Munoz F, et al. Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci. 2017;62(2):481\u201390.","journal-title":"Dig Dis Sci"},{"key":"2766_CR61","unstructured":"Gazetta Ufficiale. Gazetta Ufficiale della Republica Italiana. 2023. https:\/\/www.gazzettaufficiale.it\/. Accessed Nov 2022."},{"key":"2766_CR62","unstructured":"IQVIA. Syndicated data: Italian market share and incident \/ prevalent population data. 2022."},{"key":"2766_CR63","unstructured":"IQVIA. Syndicated data: Italian biosimilar volume data. 2022."},{"key":"2766_CR64","unstructured":"IQVIA. Syndicated data: Italian patient volume data. January 2017\u2013December 2019. 2019."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02766-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T18:13:46Z","timestamp":1714155226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02766-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2766"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02766-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fareen Hassan, Sarah Alulis and Jennifer Norma Barthelmes are employees of Janssen-Cilag with stock or share ownership. Rose Hart, Dawn Lee, Jennifer Boer, and Karl Patterson are\/were employees of Lumanity, a company that performs commissioned health-economic related work for several pharmaceutical companies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}